



Fostamatinib

Immunthrombozytopenie (ITP) » rezidiert/refraktär

Empfehlungen der Fachgesellschaft zum Einsatz neuer Arzneimittel

Herausgeber

DGHO Deutsche Gesellschaft für Hämatologie und
Medizinische Onkologie e.V.
Bauhofstr. 12
10117 Berlin

Geschäftsführender Vorsitzender: Prof. Dr. med. Andreas Hochhaus

Telefon: +49 (0)30 27 87 60 89 - 0

info@dgho.de

www.dgho.de

Ansprechpartner

Prof. Dr. med. Bernhard Wörmann
Medizinischer Leiter

Quelle

www.onkopedia.com

Die Empfehlungen der DGHO für die Diagnostik und Therapie hämatologischer und onkologischer Erkrankungen entbinden die verantwortliche Ärztin / den verantwortlichen Arzt nicht davon, notwendige Diagnostik, Indikationen, Kontraindikationen und Dosierungen im Einzelfall zu überprüfen! Die DGHO übernimmt für Empfehlungen keine Gewähr.

Inhaltsverzeichnis

1 Fostamatinib, ITP, relapsed/refractory	2
---	----------

Fostamatinib

Dokument: Fact Sheet

Spezifizierung: Immunthrombozytopenie (ITP) » rezidiert/refraktär

Stand: November 2020

1 Fostamatinib, ITP, relapsed/refractory

Fostamatinib, ITP, relapsed/refractory

onkopedia				Facts		Appraisal																																					
Parameter	Results¹⁴	HR¹⁵	p value	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 10%;"></td> <td style="width: 10%; text-align: center;">5</td> <td style="width: 10%; text-align: center;">4</td> <td style="width: 10%; text-align: center;">3b</td> <td style="width: 10%; text-align: center;">3a</td> <td style="width: 10%; text-align: center;">2c</td> <td style="width: 10%; text-align: center;">2b</td> <td style="width: 10%; text-align: center;">2a</td> <td style="width: 10%; text-align: center;">1b</td> <td style="width: 10%; text-align: center;">1a</td> </tr> <tr> <td style="padding: 5px;">Evidence (LoE)</td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="background-color: black; border: 1px solid black; width: 20px; height: 20px;"></td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> </tr> <tr> <td style="padding: 5px;">Clinical benefit (ESMO MCBS)</td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> <td style="border: 1px solid black; width: 20px; height: 20px;"></td> </tr> </table>											5	4	3b	3a	2c	2b	2a	1b	1a	Evidence (LoE)										Clinical benefit (ESMO MCBS)									
	5	4	3b	3a	2c	2b	2a	1b	1a																																		
Evidence (LoE)																																											
Clinical benefit (ESMO MCBS)																																											
<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 15%;">SAE⁷</td> <td style="width: 15%;">15 vs 16</td> <td style="width: 15%;"></td> <td style="width: 15%;">n.s.¹⁶</td> </tr> <tr> <td>SR¹¹</td> <td>2¹⁹ vs 18¹⁹</td> <td></td> <td>p = 0.0003</td> </tr> <tr> <td>OR¹²</td> <td>14²⁰ vs 43²⁰</td> <td></td> <td>p = 0.0006</td> </tr> </table>				SAE⁷	15 vs 16		n.s.¹⁶	SR¹¹	2¹⁹ vs 18¹⁹		p = 0.0003	OR¹²	14²⁰ vs 43²⁰		p = 0.0006	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 10%;"></td> <td style="width: 10%; text-align: center;">1</td> <td style="width: 10%; text-align: center;">2</td> <td style="width: 10%; text-align: center;">3</td> <td style="width: 10%; text-align: center;">4</td> <td style="width: 10%; text-align: center;">5</td> </tr> <tr> <td style="padding: 5px;">Legend</td> <td colspan="5" style="padding: 5px;"> ■ curative ■ non-curative </td> </tr> </table>											1	2	3	4	5	Legend	■ curative ■ non-curative										
SAE⁷	15 vs 16		n.s.¹⁶																																								
SR¹¹	2¹⁹ vs 18¹⁹		p = 0.0003																																								
OR¹²	14²⁰ vs 43²⁰		p = 0.0006																																								
	1	2	3	4	5																																						
Legend	■ curative ■ non-curative																																										
<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 15%;">Patients</td> <td style="width: 85%;">relapsed / refractory</td> </tr> <tr> <td>Trial</td> <td>Phase 3</td> </tr> <tr> <td>Randomisation</td> <td>2 : 1</td> </tr> <tr> <td>N¹</td> <td>150</td> </tr> <tr> <td>New Therapy</td> <td>Fostamatinib</td> </tr> <tr> <td>Control</td> <td>Standard of Care</td> </tr> <tr> <td>Publication</td> <td>DOI:10.1002/ajh.25125</td> </tr> </table>				Patients	relapsed / refractory	Trial	Phase 3	Randomisation	2 : 1	N¹	150	New Therapy	Fostamatinib	Control	Standard of Care	Publication	DOI:10.1002/ajh.25125																										
Patients	relapsed / refractory																																										
Trial	Phase 3																																										
Randomisation	2 : 1																																										
N¹	150																																										
New Therapy	Fostamatinib																																										
Control	Standard of Care																																										
Publication	DOI:10.1002/ajh.25125																																										

Legende:

¹ N - number of patients

⁷ SAE - serious adverse events, CTCAE grade 3/4

¹¹ SR - sustained response

¹² OR - overall response

¹⁴ results for control, results for new therapy

¹⁵ hazard ratio for new therapy

¹⁶ n. s. not significant

¹⁹ platelets $\geq 50 \times 10^9/L$ on 4 of 6 visits between week 14 and 24

²⁰ platelets $\geq 50 \times 10^9/L$ within 12 weeks